Boehringer and Eli Lilly to conduct large trial of Jardiance(empagliflozin) to treat chronic kidney disease.

Boehringer Ingelheim and Eli Lilly and Company announced plans to conduct a new, large clinical outcomes trial investigating Jardiance (empagliflozin) tablets for the treatment of people with chronic kidney disease. The trial will enroll people with chronic kidney disease both with and without type 2 diabetes.

Jardiance is the first and only type 2 diabetes medicine approved to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease. The landmark EMPA-REG OUTCOME trial demonstrated that Jardiance reduced the risk of cardiovascular death by 38 percent versus placebo in people with type 2 diabetes and established cardiovascular disease when added to standard of care (including glucose-lowering agents and cardiovascular drugs). As one of the secondary endpoints, the trial also showed that Jardiance reduced the risk for new-onset or worsening of kidney disease by 39 percent versus placebo when added to standard of care in adults with type 2 diabetes and established cardiovascular disease. Based on these results, BI and Lilly decided to formally investigate the potential of Jardiance in people with chronic kidney disease. This and other ongoing mechanistic studies will allow the companies to further explore the potential mechanisms - including the reduction in glomerular pressure - by which empagliflozin may impact renal outcomes in those with chronic kidney disease.